Evidence map›Paper›PMID 41324787›Full record

ReviewDrugs2026

Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don't Know.

Edward K Silberman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Edward K SilbermanTufts University School of Medicine, Boston, MA, USA. Edward.Silberman@tufts.edu.ORCID http://orcid.org/0000-0002-8895-4903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benzodiazepines, first introduced in the 1960s as effective and safer alternatives to barbiturate sedative-hypnotics, are now widely viewed as having a high risk of overdose, abuse, addiction, and "dependency". These beliefs are contrary to extensive scientific evidence. Systematic research has shown that prescribed benzodiazepines are not prone to tolerance, dose-escalation, abuse, or addiction. Benzodiazepine abuse and overdose fatalities occur largely in the context of established polysubstance abuse. They are as effective as antidepressants and have fewer adverse effects but similar withdrawal syndromes. Major adverse effects are impairment of coordination, memory, and cognition, of most concern in older populations, and increased risk of motor vehicle accidents, especially when used along with alcohol. Most patients can be withdrawn from benzodiazepines without major difficulty using clinician supportiveness and flexible tapers. Reports of severe adverse reactions to benzodiazepines and of severe, prolonged difficulties withdrawing from them have not been subjects of systematic study and are poorly understood. In summary, the literature supports use of benzodiazepines on par with antidepressants for anxiety disorders, and for benzodiazepines and z-drugs for short-term mitigation of insomnia.

Indexed as

Azabicyclo CompoundsBenzodiazepinesHypnotics and SedativesAntidepressive AgentsAnxiety DisordersHumansSleep Initiation and Maintenance DisordersSubstance-Related DisordersSubstance Withdrawal SyndromeAntidepressive AgentsAzabicyclo CompoundsBenzodiazepinesHypnotics and Sedatives

Identifiers

PMID41324787

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.